American Urological Association

DigitCells Unveils Proprietary TWO-D system at AUA 2024, Revolutionizing Pathology Workflows

Retrieved on: 
Dienstag, April 30, 2024
Prostate, American Urological Association, Breast, LIS, Pathology, Intelligence, Digital, Environment, GI, Marie Cassidy, Histology, Acquisition, IMS, AUA, Annual general meeting, Medical director, Dermatology, Overalls, Medical imaging

CHICAGO, April 30, 2024 /PRNewswire-PRWeb/ -- DigitCells, a leading innovator in complete digital pathology solutions and a subsidiary company of GoPath Diagnostics, is excited to announce the launch of its groundbreaking Tissue Workflow Optimization for Digital (TWOD) system for prostate at the upcoming 2024 American Urological Association (AUA) Annual Meeting in San Antonio, Texas.

Key Points: 
  • The TWOD system represents a revolutionary leap in pathology workflows, delivering unprecedented efficiency gains and setting a new benchmark in digital pathology."
  • Dr. Jim Lu, CEO and Medical Director of GoPath Diagnostics
    The TWOD system streamlines biopsy tissue workflows, significantly enhancing efficiency to meet the demands of today's pathology environment.
  • This process is centrally managed by TWOD's LIS and IMS system which integrates laboratory information and pathology imaging with embedded augmented intelligence and pathology sign-out functions.
  • The TWOD system bridges the gap between histopathology and digital pathology, reducing cost and improving workflow efficiency.

AUA/SUFU Guideline on the Treatment of Overactive Bladder Allows Access to ReviTM System Earlier in Treatment Journey

Retrieved on: 
Montag, April 29, 2024
FDA, Commercial software, Society, Risk, Urinary incontinence, Food, De novo, American Urological Association, Paruresis, Pharmacotherapy, MMHC, Guideline, OAB, Deficit spending, Prescription, Patient, Neuromodulation, Physician, AUA, Ankle, Diagnosis, SUFU, Anticholinergic, Female

The revised guidelines are a major affirmation of the importance of Revi as a therapy for patients with UUI.

Key Points: 
  • The revised guidelines are a major affirmation of the importance of Revi as a therapy for patients with UUI.
  • First, the guidelines were updated to include iTNM as an acceptable minimally invasive therapy.
  • "We are delighted to witness the transformation of the new OAB treatment guideline by the AUA/SUFU.
  • This guideline represents a significant turning point in physicians' approach to OAB management," commented Dan Lemaitre, Chief Executive Officer of BlueWind Medical.

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Retrieved on: 
Freitag, April 26, 2024
American Urological Association, Carcinoma, Mayo Clinic, Patient, Treatment, Bladder cancer, High Risk, AUA

IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, will host a virtual investor event on Friday, May 3, 2024, at 4:30pm EDT.

Key Points: 
  • IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, will host a virtual investor event on Friday, May 3, 2024, at 4:30pm EDT.
  • The executive leadership team will provide updates on the company’s progress, following an oral presentation of its oncolytic immunotherapy cretostimogene at the American Urological Association (AUA) Annual Meeting in San Antonio, TX.
  • CG Oncology will broadcast the presentations live on the company's investor relations website, https://ir.cgoncology.com , where a webcast replay will also be available following the event.
  • Details of the AUA oral presentation are as follows:
    Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
    Presenter: Mark D. Tyson, M.D., Urologic Oncologist at Mayo Clinic, Scottsdale, AZ

AUA, ASCO, SUO Release Amendment to Non-Metastatic Muscle Invasive Bladder Cancer Guideline

Retrieved on: 
Donnerstag, April 25, 2024
Society, African Americans, American Urological Association, Partnership, Guideline, ASCO, Therapy, Patient, NMIBC, AUA, Diagnosis, E pluribus unum, Bladder cancer, SUO, Medical device

There are over 83,000 new cases of bladder cancer and nearly 17,000 bladder cancer deaths estimated for 2024 in the U.S. Up to 50% or more of patients with high-risk non-muscle invasive bladder cancer (NMIBC) can progress to invasive disease.

Key Points: 
  • There are over 83,000 new cases of bladder cancer and nearly 17,000 bladder cancer deaths estimated for 2024 in the U.S. Up to 50% or more of patients with high-risk non-muscle invasive bladder cancer (NMIBC) can progress to invasive disease.
  • While rates of bladder cancer are higher in Caucasians than other ethnicities, disease-specific survival is worse overall for African Americans.
  • “The landscape for the management of muscle-invasive bladder cancer continues to change with the advent of new therapies, techniques, and adjuvant care,” said Dr. Jeffrey M. Holzbeierlein, former SUO president and chair for the guideline amendment.
  • “This amendment to the previous muscle invasive bladder cancer guidelines will help clinicians appropriately manage these complex patients.”
    Text supporting statements on neoadjuvant/adjuvant chemotherapy, pelvic lymphadenectomy, and multi-modal bladder preserving therapy was updated to include newly available data and updated discussion.

AUA, SUFU Release Guideline on Diagnosis and Treatment of Overactive Bladder

Retrieved on: 
Dienstag, April 23, 2024
Society, Phenotype, Woman, American Urological Association, MD, Partnership, Pelvic floor dysfunction, Guideline, OAB, Obesity, Patient, Overactive bladder, AUA, Constipation, Diagnosis, SUFU, Quality of life, Prevalence, Systematic review, Medical device

BALTIMORE, April 23, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), released the 2024 clinical practice guideline for the diagnosis and treatment of overactive bladder (OAB).

Key Points: 
  • BALTIMORE, April 23, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), released the 2024 clinical practice guideline for the diagnosis and treatment of overactive bladder (OAB).
  • As OAB is a symptom-based diagnosis, the impact of the symptoms on quality of life is critical to the condition.
  • The degree of bother caused by OAB symptoms directly affects OAB care-seeking, treatment intensity, and satisfaction with treatment.
  • The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder.

PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting

Retrieved on: 
Dienstag, April 23, 2024
Urology, Safety, American Urological Association, Abstract, ASC, LUTS, Surgeon, TURP, Patient, AMVETS, SDD, AUA, Robotics, Biorobotics, Health, USAV, Clinical trial, SAN, BPH

PROCEPT BioRobotics is exhibiting at booth #1429 and will be conducting hands-on workshops and surgeon presentations throughout the meeting.

Key Points: 
  • PROCEPT BioRobotics is exhibiting at booth #1429 and will be conducting hands-on workshops and surgeon presentations throughout the meeting.
  • “The growing body of real-world clinical evidence on Aquablation therapy is reflected by the extensive range of presentations being showcased at the AUA,” said Reza Zadno, CEO of PROCEPT BioRobotics.
  • The continued momentum and interest in Aquablation therapy are a testament to our unwavering commitment to advancing innovative, safe and effective treatment options for patients.”
    Registered attendees can access the full list of Aquablation therapy presentations here.
  • PROCEPT BioRobotics will sponsor additional satellite events during AUA at both the Henry B. Gonzalez Convention Center and off-site, including:

EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting

Retrieved on: 
Dienstag, April 23, 2024
Plenary session, Clinical trial, Prostate cancer, American Urological Association, EDAP, AUA, Medical imaging

LYON, France, April 23, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that final results from the HIFI Study, the largest clinical trial ever conducted comparing EDAP’s Focal One robotic high intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) for the treatment of prostate cancer, will be presented during a plenary session at the 119th American Urological Association Annual Meeting (AUA 2024), which is taking place from May 3-6, 2024, in San Antonio, Texas, USA.

Key Points: 
  • LYON, France, April 23, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that final results from the HIFI Study, the largest clinical trial ever conducted comparing EDAP’s Focal One robotic high intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) for the treatment of prostate cancer, will be presented during a plenary session at the 119th American Urological Association Annual Meeting (AUA 2024), which is taking place from May 3-6, 2024, in San Antonio, Texas, USA.
  • Plenary Session: P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: HIFI trial: HIFU vs Radical prostatectomy for localized Prostate cancer in 3328 cases.
  • Final results.
  • Location:                      Stars at Night Ballroom (Henry B. Gonzalez Convention Center)

Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer

Retrieved on: 
Mittwoch, Mai 1, 2024
Health, Technology, Health Technology, Artificial Intelligence, Oncology, Jane, Risk, American Urological Association, Recurrence, BCG, Docetaxel, CHAI, Data, University, Patient, Histology, Physician, AUA, Multimedia, Toxicity, Biomarker, Neoplasm, Associate, Medicine, Bladder cancer, Labs, Medical imaging

The biomarkers were successfully validated across 1000+ patients and 12 centers on four end-points, making it the largest validation study of its kind in bladder cancer.

Key Points: 
  • The biomarkers were successfully validated across 1000+ patients and 12 centers on four end-points, making it the largest validation study of its kind in bladder cancer.
  • View the full release here: https://www.businesswire.com/news/home/20240501832149/en/
    The CHAI biomarkers offer independent prognostic capabilities for high-grade recurrence and muscle-invasive progression in bladder cancer.
  • Validated across more than 1,000 patients and 12 centers, these biomarkers, available through the Vesta test, can enhance first-line treatment decision-making for non-muscle invasive bladder cancer.
  • We are able to visualize these biomarkers and gain a better understanding of how tumor morphology correlates to treatment response.”

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

Retrieved on: 
Donnerstag, April 25, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, RWE, EDT, Cancer Moonshot, Lung cancer, Hope, Nivolumab, American Urological Association, Second, Pembrolizumab, Survival, Immunotherapy, American Cancer Society, Webcast, BCG, Disease, Patient, Medicine, AUA, Multimedia, Death, NK, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240424428572/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240424428572/en/
    In NSCLC patients who relapsed or were refractory to checkpoint inhibitors, ANKTIVA was administered together with the same checkpoint inhibitor.
  • The addition of ANKTIVA resulted in the rescue of the checkpoint therapy efficacy, with significant prolongation of overall survival.
  • This prolongation of survival in NSCLC following checkpoint failure is consistent with ImmunityBio’s findings of durable complete responses following BCG failure in NMIBC.
  • According to the American Cancer Society, lung cancer is the second most common cancer in the U.S.

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

Retrieved on: 
Mittwoch, April 17, 2024
Research, Clinical Trials, Health Technology, Practice Management, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Recurrence, American Urological Association, Abstract, LG, AUA, Mitomycins, Annual general meeting, ATLAS, Medical device

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on investigational drug UGN-102 (mitomycin) and JELMYTO and will be presented at the American Urological Association (AUA) 2024 Annual Meeting being held in San Antonio, Texas from May 3 – 6.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on investigational drug UGN-102 (mitomycin) and JELMYTO and will be presented at the American Urological Association (AUA) 2024 Annual Meeting being held in San Antonio, Texas from May 3 – 6.
  • “We are proud that the AUA selected the ATLAS post-hoc analysis as a podium presentation,” said Mark Schoenberg, M.D., Chief Medical Officer, UroGen.
  • “The results highlight UGN-102’s potential to help significantly advance treatment for patients with newly diagnosed and recurrent LG-IR-NMIBC, a highly prevalent and recurrent disease.
  • Additionally, we are excited to see additional independent real-world evidence related to JELMYTO treatment of LG-UTUC patients in a diverse patient types.”
    Key details of UGN-102 and JELMYTO abstracts accepted by AUA:
    Response to Primary Chemoablation with UGN-102 in Patients with New or Recurrent LG IR NMIBC: Post-hoc Analysis of the ATLAS Trial